Evotec places €116.1 million convertible bonds due 2033 By Investing.com

Evotec placed €116.1 million of 7-year senior unsecured convertible bonds with a 2.625% coupon, a 110% redemption value at maturity, and a 3.882% yield to maturity. The deal includes a 37.5% conversion premium at an initial conversion price of €6.5313 and is intended to fund Project Horizon cash requirements. A concurrent share placement was used only for hedging and will not provide proceeds to Evotec.

Analysis

This is less a financing event than a delayed balance-sheet bridge to buy time for a turnaround that still has to prove it can self-fund. The convertible structure shifts downside risk away from immediate dilution and onto future equity optionality, but the real pressure point is whether the market continues to underwrite the transformation plan before operating performance stabilizes. If the company cannot show sequential margin repair over the next 2-3 quarters, the bond will likely trade more like distressed equity optionality than a clean hybrid.

The second-order winner is the bank syndicate and short-term hedge flow, not the issuer’s equity. The concurrent share sale effectively monetizes demand from convertible buyers while capping near-term squeeze dynamics; that usually leaves the stock vulnerable once the book-building technical support fades. For equity holders, the issue is not dilution at maturity so much as the overhang from a large conversion strike well above spot, which can suppress multiple expansion until investors see evidence that the turnaround is gaining traction.

The key catalyst set is operational, not financial: next two earnings prints, any guidance on cash burn, and whether Project Horizon starts converting into lower overhead and better gross margin. If revenue weakness persists into the next cycle, the market will start treating the convertible as a warning signal that equity dilution is probable well before maturity. Conversely, a clean beat-and-raise plus evidence of improving utilization could re-rate the stock because the financing removes near-term solvency anxiety.

Contrarian view: the market may be overreacting to the dilution optics and underestimating how much optionality the new capital buys. If the company can arrest cash burn, the current valuation can work off a low base because the equity is already pricing in substantial execution risk. The setup is asymmetric: the bonds are a carry vehicle with embedded equity upside, while the common is a high-beta recovery trade that needs proof fast.

Key Decisions for Investors

• Avoid chasing EVO common into the financing-clearing window; wait 2-4 weeks for post-placement drift to see if technical support fades. Best risk/reward is lower entry after the deal-related overhang settles.
• For tactical longs, consider a small starter position in EVO common only on confirmation that next quarter cash burn improves; downside is still material if Project Horizon slips, but upside can expand sharply on a credible turnaround.
• Pair trade: long EVO convert or equity-linked exposure versus short a basket of slower-turnaround European life-science services names over 3-6 months. If management executes, EVO should outperform on de-risking and financing relief; if not, the pair limits broad sector risk.
• Use puts or a collar on EVO common into the next earnings date if holding through the catalyst. The stock is likely to trade on guidance quality, and the financing removes some bankruptcy risk but not execution risk.
• Monitor the bond secondary market for a weak tape over the next 1-2 months; if the convertible trades materially below par, it signals the market is pricing in either more dilution or slower-than-expected operating repair.